Full Press Release Details
Zai Lab Announces First Patient Dosed in Greater China in Global Registrational Clinical Trial of Efgartigimod in Primary Immune Thrombocytopenia.
ZLAB
Zai Lab Announces First Patient Dosed in Greater China in Global Registrational Clinical Trial of Efgartigimod in Primary Immune Thrombocytopenia
Key Takeaway: Zai Lab Announces First Patient Dosed in Greater China in Global Registrational Clinical Trial of Efgartigimod in Primary Immune Thrombocytopenia